一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Toripalimab；Nab paclitaxel；Pemetrexed；Carboplatin，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Toripalimab；Nab paclitaxel；Pemetrexed；Carboplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences · 广州
公开的入选条件
- 1. Age: 18 Years and older
- 2. ECOG physical score 0-1 points; expected survival time ≥ 3 months;
- 3. Pathologically confirmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET amplification (FISH confirmed) or exon 14 skippin
- 4. Lung function capacity capable of tolerating the proposed lung surgery
- 5. Available tissue of tumor for PD-L1 test
- 6. Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05800340；登记信息更新于 2023-04-05。